Jake is a seasoned biopharmaceutical industry executive. He currently serves on the Board of Enliven Therapeutics, Phoenix Tissue Repair, Inc. and Arya Sciences Acquisition Corp V. Prior to MyoKardia Inc.’s acquisition by Bristol Myers Squibb, Jake served as the Chief Business Officer of MyoKardia, Inc. Prior to this, he served as Senior Vice President, Finance and Corporate Development and Principal Financial Officer and as Vice President, Business Development and Business Operations of MyoKardia, Inc.
Prior to joining MyoKardia, Inc., Jake served as Vice President, Business Operations and head of corporate development at Ablexis, LLC and as a principal at Third Rock Ventures. While at Third Rock Ventures, he was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc., CytomX Therapeutics Inc., and Global Blood Therapeutics, Inc. Previously, Jake served in roles in the investment group at Royalty Pharma AG, the business development group at Endo Pharmaceuticals Inc. and as a management consultant at Putnam Associates.
Jake holds a B.S. in biology and a B.A. in economics from Duke University and an M.B.A. from Harvard Business School.